Definiens has released Definiens TissueMap 2.0 for oncology research. The image analysis software application provides detailed, automated morphometric quantification of biomarkers of nuclei or cell bodies in epithelial tumours or xenografts.
The effective use of imaging technologies, such as Definiens TissueMap 2.0, significantly improves the selection and prioritisation of quality candidates early in the drug development pipeline. This results in substantial cost savings and faster time-to-market as poorer drug candidates are removed early in the discovery process.
The application features the detection of viable and necrotic tissue in xenografts, as well as regions of IHC (DAB) positively stained nuclei or cells in the viable tissue. This enables pathologists to automate the process of complex or highly apoptotic xenograft analysis in oncology research.
Definiens TissueMap 2.0 enables the quantification of biomarker expression patterns in image data regardless of staining methodology. The software application effectively analyses image data in oncology research, including cases involving poor staining technique and data obtained from heterogeneous equipment.
